DCC-3014 is an investigational medication being studied for its safety and effectiveness in treating patients with advanced tumors and tenosynovial giant cell tumor (TGCT). The trial aims to understand how the body processes this medication and to find the most suitable dose for future studies. Researchers are also looking at how well DCC-3014 works in shrinking or controlling the tumors.

Advanced Tumors – Advanced tumors refer to cancerous growths that have progressed to a late stage, often spreading beyond their original site to other parts of the body. These tumors can affect various organs and tissues, leading to a range of symptoms depending on their location and size. As they grow, they may invade nearby structures and disrupt normal bodily functions. The progression of advanced tumors can vary widely, with some growing slowly over time, while others may spread rapidly. The impact on the body can be significant, often causing pain, fatigue, and other systemic effects.

Tenosynovial Giant Cell Tumor – Tenosynovial giant cell tumor is a rare, typically benign tumor that arises in the synovial lining of joints, tendons, or bursae. It is characterized by the proliferation of synovial-like cells, leading to swelling and pain in the affected area. The tumor can be localized or diffuse, with the localized form often presenting as a single mass, while the diffuse form can involve larger areas. Over time, the tumor may cause joint stiffness and reduced mobility due to its growth and pressure on surrounding tissues. Although it is generally non-cancerous, it can cause significant discomfort and functional impairment.